Today’s Research Reports on Covalon Technologies, DiaMedica Therapeutics, Emerald Health Therapeutics and Sernova Corp.
NEW YORK, NY / ACCESSWIRE / October 13, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI has Initiated Coverage Today on:
Covalon Technologies Ltd. - https://rdinvesting.com/news/?ticker=COV.V (TSX-V: COV)
DiaMedica Therapeutics Inc. - https://rdinvesting.com/news/?ticker=DMA.V (TSX-V: DMA)
Emerald Health Therapeutics, Inc. - https://rdinvesting.com/news/?ticker=EMH.V (TSX-V: EMH)
Sernova Corp. - https://rdinvesting.com/news/?ticker=SVA.V (TSX-V: SVA)
Covalon Technologies Ltd.'s (TSX-V: COV) stock moved 1.04% lower Thursday, to close the day at $3.79. The stock recorded a trading volume of 6,900 shares, which was below its three months average volume of 15,221 shares. In the last year Covalon Technologies Ltd.'s shares have traded in a range of 1.45 - 4.60. The share price has gained 161.38% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $3.37 is greater than its 200-day moving average of $2.50. Shares of Covalon Technologies have gained approximately 119.08 percent year-to-date.
Access RDI's Covalon Technologies Ltd. Research Report at: https://rdinvesting.com/news/?ticker=COV.V
On Thursday, shares in DiaMedica Therapeutics Inc. (TSX-V: DMA) recorded a trading volume of 37,500 shares, which was below the three months average volume of 55,679 shares. The stock ended the day 5.00% lower at 0.38. The share price has gained 171.43% from its 52 week low with a 52 week trading range of 0.14 - 0.42.The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $0.32 is greater than its 200-day moving average of $0.30. Shares of DiaMedica Therapeutics have gained approximately 111.11 percent year-to-date.
Access RDI's DiaMedica Therapeutics Inc. Research Report at: https://rdinvesting.com/news/?ticker=DMA.V
Emerald Health Therapeutics, Inc.'s (TSX-V: EMH) stock moved 5.16% lower Thursday, to close the day at $1.47. The stock recorded a trading volume of 1,220,148 shares, which was above its three months average volume of 276,219 shares. In the last year Emerald Health Therapeutics, Inc.'s shares have traded in a range of 0.68 - 2.19. The share price has gained 116.18% from its 52 week low. The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $1.25 is below its 200-day moving average of $1.98.Shares of Emerald Health Therapeutics have gained approximately 13.08 percent year-to-date.
Access RDI's Emerald Health Therapeutics, Inc. Research Report at: https://rdinvesting.com/news/?ticker=EMH.V
On Thursday, shares in Sernova Corp. (TSX-V: SVA) recorded a trading volume of 20,500 shares, which was below the three months average volume of 120,262 shares. The stock ended the day flat at 0.19. The share price has gained 31.03% from its 52 week low with a 52 week trading range of 0.14 - 0.32.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $0.20 is below its 200-day moving average of $0.22. Shares of Sernova have fallen approximately 36.67 percent year-to-date.
Access RDI's Sernova Corp. Research Report at: https://rdinvesting.com/news/?ticker=SVA.V
Our Actionable Research on Covalon Technologies Ltd. (TSX-V: COV), DiaMedica Therapeutics Inc. (TSX-V: DMA), Emerald Health Therapeutics, Inc. (TSX-V: EMHV) and Sernova Corp. (TSX-V: SVA) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer:
This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
